BioSpace News Archive

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced plans to focus development of its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH).

Allarity Therapeutics, Inc. announced that the Company’s 2022 Annual Meeting of Stockholders, was convened on November 4, 2022, at 1:00 p.m. and was adjourned without any business being conducted.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, announced it will be participating in the Q4 Investor Summit Conference, which will take place on November 14, 2022 in New York, New York.

Every year, approximately 8 million Americans are susceptible to dangerous, often fatal blood clots when they are admitted to the hospital for a medical illness such as stroke or an infection like COVID-19.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the presentation of new data from the Phase 3 RAPID clinical trial of etripamil, the Company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it will participate in the Guggenheim 4th Annual Immunology and Neurology Day, November 14th and 15th.

AbbVie (NYSE: ABBV) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients.

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) were presented during the late-breaking session at The Liver Meeting® 2022.

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of COVID-19 in adult and pediatric patients, reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Rhythm Pharmaceuticals, Inc. announced that on November 3, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 23,400 shares of its common stock to two new employees, consisting of inducement stock options to purchase an aggregate of 15,600 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 7,800 shares of its common stock.